Navigation Links
PTEN: the Treg's handbrake

Naturally occurring CD4+CD25+ Tregs are a specialized subpopulation of T cells that function to prevent other T cells destroying self-tissues. But harnessing the therapeutic potential of Tregs -- for example, to treat autoimmune diseases such as diabetes and rheumatoid arthritis -- is hampered by problems generating sufficient cells to be therapeutically effective. This is because, unlike non-regulatory T cells, Tregs do not proliferate in vitro when stimulated through either their TCR or IL-2 receptor alone.

Now, in a study appearing online on August 17 in advance of print publication in the September issue of the Journal of Clinical Investigation, Laurence Turka and colleagues from the University of Pennsylvania have shown that Tregs from mice with T cells that lack phosphatase and tensin homolog (PTEN) proliferate in response to IL-2. Importantly, PTEN-deficient Tregs retained their suppressive function in vitro and in vivo, indicating that loss of PTEN by Tregs only affects their proliferative capabilities in response to IL-2 and not their other functions. These results identify PTEN as a key protein that regulates the lack of responsiveness of Tregs to IL-2 and could provide researchers with a way to overcome one of the biggest obstacles to harnessing their therapeutic potential.


'"/>

Source:Journal of Clinical Investigation


Page: 1

Related biology news :

1. NHGRI targets 12 more organisms for genome sequencing
2. NHGRI Selects 13 More Organisms for Genome Sequencing
3. NHGRI expands effort to revolutionize sequencing technologies
4. NHGRI announces new sequencing targets
5. NHGRI aims to make DNA sequencing faster, more cost effective
6. Wiley announces publication of Databasing the Brain
7. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
8. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
9. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
10. GlycoFi announces the first production of antibodies with human glycosylation in yeast
11. CHAVI announces international search for genes affecting HIV response
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: PTEN the Treg handbrake

(Date:2/24/2015)... 2015 This report analyzes the worldwide markets for Face ... Biometrics, and Voice Biometrics. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific , ... , and Latin America . Annual estimates and ... seven-year historic analysis is provided for these markets. Market data and ...
(Date:2/18/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. , Cowen and Company ... March 3, 2015 at 11.20 a.m. Eastern Time , ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... for these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... brain to release endorphins, bringing real relief to those ... relieve pain is enough to prompt the brain to ... a new University of Michigan study finds. , The ... own pain-fighting chemicals, called endorphins, play a role in ...
... days of voluntary bedrest in order to simulate the ... research team in Toulouse, France, is now actively seeking ... enhance the research. , At the beginning of June, ... WISE study (Women International Simulation Experiment), were progressively 'released' ...
... lifespan extension in yeast have been identified by researchers from ... intake, or caloric restriction, is known to extend the lifespan ... a gene called Sir2 with lifespan extension due to caloric ... longer when put on a tough diet, showing that some ...
Cached Biology News:Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 2Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 3Thinking the pain away? Study shows the brain's painkillers may cause 'placebo effect' 4Female volunteers prepare for a second 'bedrest' 2
(Date:2/26/2015)... BioEnterprise today announced that Northeast Ohio ... in growth funding during the past 13 years.  Funding ... – including the Ohio Third Frontier - and federal ... raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
(Date:2/26/2015)... 26, 2015 Already well respected for ... by expanding its Length Gauge offerings with new variants ... , Specifically, HEIDENHAIN’s pencil probe-style SPECTO length gauge ... Two new 1Vpp, 12mm stroke length variants of ... One is a variant with a weak spring, 0.4N ...
(Date:2/26/2015)... February 26, 2015 RURO, Inc., a ... FreezerPro® version 6.2 – the latest update to the ... is that of a quick and easy method to ... the latest version, RURO engineering has enhanced the system’s ... move large amounts of sample records. , "FreezerPro ...
(Date:2/26/2015)... , Feb. 26, 2015  Dyadic International, ... whose patented and proprietary technologies are used to ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... its financial results for year ending December 31, ... 2015 and will host a conference call that ...
Breaking Biology Technology:More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2RURO Releases FreezerPro® version 6.2 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3
... Sanaria,s mission is to develop and commercialize whole-parasite malaria ... by Plasmodium falciparum and P. vivax ... has developed the capacity to manufacture and assay malaria ... industrial setting. These parasites, mosquitoes, and assay services are ...
... PharmaNet Development Group, Inc., a leading provider of ... medical device companies, announced today that Joel Posener, MD, ... Dr. Posener will support PharmaNet project teams conducting clinical ... development advice to clients in the area of ...
... 29, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... therapeutic and preventive vaccines against cancers and infectious diseases, ... cancer showed remarkable immune responses in monkeys, following similarly ... reported data from earlier animal studies. The data was ...
Cached Biology Technology:Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria 2Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria 3Dr. Joel Posener Joins PharmaNet as Executive Medical Director, Neuroscience 2Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 2Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 3Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 4Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 5Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 6
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Request Info...
Biology Products: